DRUG RELATED PROBLEM PADA PASIEN MULTI DRUG RESISTANT TUBERCULOSIS (TB MDR) RAWAT JALAN
DOI:
https://doi.org/10.23917/ujp.v4i2.563Keywords:
Drug related problems, TB MDR rawat jalanAbstract
Tuberkulosis Multi Drug Resistant (TB MDR) merupakan kondisi kuman Mycobacterium tuberculosis yang telah resisten terhadap isoniazid dan rifampisin dengan atau tanpa OAT lainnya. Banyaknya jumlah obat pada terapi TB MDR serta rendahnya angka keberhasilan pengobatan mendorong untuk mengevaluasi permasalahan terkait pengobatan (DRPs) yang terjadi pada pasien TB MDR tersebut. Penelitian ini dilakukan dengan pendekatan deskriptif observasional metode potong lintang. Pengamatan sampel dilakukan secara prospektif pada pasien TB MDR rawat jalan di RSUD Dr. Moewardi Surakarta dan RSP Ario Wirawan Salatiga. Klasifikasi DRPs mengacu pada klasifikasi pharmaceutical care network Europe versi 8.02. Kejadian DRPs pada pasien rawat jalan TB MDR terjadi pada seluruh pasien (117 pasien) dengan total 168 kasus. DRPs kategori efektifitas terapi 29,51% (51 kasus), DRPs kategori keamanan terapi 70,49% (117 kasus).
Downloads
References
Alavi-Naini, R., Sharifi-mood, B., & Metanat, M. (2012). Association between tuberculosis and smoking. International Journal of High Risk Behaviors & Addiction, 1(2), 71–74. https://doi.org/10.5812/ijhrba.5215
Arini, Y. D., Rahmawati, F., & Andayani, T. M. (2016). Faktor resiko kejadian drug related problems pada pasien penyakit kronis rawat jalan di poliklinik penyakit dalam. Jurnal Manajemen dan Pelayanan Farmasi, 6(2), 83–94. https://doi.org/10.22146/jmpf.260
Baya, B., et al. (2019). Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. International Journal of Infectious Diseases, 81, 149–155. https://doi.org/10.1016/j.ijid.2019.02.004
Bernabe-Ortiz, A., et al. (2011). Weight variation over time and its association with tuberculosis treatment outcome: A longitudinal analysis. PLoS ONE, 6(4), 2–6. https://doi.org/10.1371/journal.pone.0018474
Bhagavathula, A. S., et al. (2017). Assessment of drug related problems and its associated factors among medical ward patients in University of Gondar Teaching Hospital, Northwest Ethiopia: A prospective cross-sectional study. Journal of Basic and Clinical Pharmacy, 8, 16–21.
Gomez, A., et al. (2015). Diabetes and other risk factors for multi-drug resistant tuberculosis in a Mexican population with pulmonary tuberculosis: Case control study. Archives of Medical Research, 1–7. https://doi.org/10.1016/j.arcmed.2015.01.006
Inayat, N., et al. (2016). Hyperuricemia and arthralgia during pyrazinamid therapy in patient with pulmonary tuberculosis. PJCM, 22(4), 154–158.
KemenKes RI. (2017). Pengobatan pasien tuberkulosis. Jakarta: DirJend Pencegahan dan Pengendalian Penyakit.
KemenKes RI. (2018). Panduan pelayanan tuberkulosis resistan obat untuk fasilitas pelayanan kesehatan. Jakarta: USAID.
Khan, I., et al. (2019). Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. Journal of Infection and Public Health, 1–7. https://doi.org/10.1016/j.jiph.2019.04.009
Nurcahya, B. M., Andayani, T. M., & Rahmawati, F. (2015). Faktor risiko terjadinya drug related problem pada pasien rawat jalan dengan penyakit kronis. Jurnal Manajemen dan Pelayanan Farmasi, 5(2), 1–6.
Patel, S. V., et al. (2015). Adverse drug reactions in patients put on multi drug resistant tuberculosis (MDR-TB) treatment in seven districts of Central Gujarat. Journal of Young Pharmacist, 7(4), 425–431. https://doi.org/10.30742/cmj.v2i1.35
PCNE. (2017). Classification for drug related problems. PCNE Classification.
Rahmatillah, D. L., et al. (2014). The evaluation of drug related problems (DRPs) of the tuberculosis (TB) patients at the lung disease ward in the installation of stayed caring of Central General Hospital Persahabatan (RSUP Persahabatan). World Journal of Pharmaceutical Research, 3(4), 13–23.
Seung, K., Rich, M., & Varaine, F. (2018). Clinical and programmatic guide for patient management with new TB drugs (Version 4.0). Eropa: endTB.
Shivaraj, G., et al. (2017). Study on drug related problems in tuberculosis patients with comorbidities in a tertiary care teaching hospital. European Journal of Pharmaceutical and Medical Research, 4(9), 756–767. https://doi.org/10.18203/2319-2003.ijbcp20203136
World Health Organization. (2014). Companion handbook to the WHO guidelines for the programmatic management of drug resistant tuberculosis. Geneva, Switzerland: WHO.
World Health Organization. (2017). Multidrug-resistant tuberculosis (MDR TB). Retrieved from http://www.who.int/tb/areas-of-work/drug-resistant-tb/
Yang, T. W., et al. (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Medicine, 28(March). https://doi.org/10.1097/MD.0000000000007482
Zhang, Y., et al. (2017). Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study. Medical Science Monitor, 23, 2348–2356. https://doi.org/10.12659/msm.904682
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Aulia Fitri, Fita Rahmawati
This work is licensed under a Creative Commons Attribution 4.0 International License.
